Basilea Pharmaceutica Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Basilea Pharmaceutica in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Basilea Pharmaceutica stock.
View analyst ratings for Basilea Pharmaceutica or view top-rated stocks.

Wall Street analysts have given Basilea Pharmaceutica a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Basilea Pharmaceutica wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Basilea Pharmaceutica's stock was trading at $44.30 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BPMUF stock has increased by 3.8% and is now trading at $46.00.
View which stocks have been most impacted by COVID-19.

Some companies that are related to Basilea Pharmaceutica include Ironwood Pharmaceuticals (IRWD), Indivior (INVVY), Xencor (XNCR), Revance Therapeutics (RVNC), ADC Therapeutics (ADCT), NGM Biopharmaceuticals (NGM), Trillium Therapeutics (TRIL), Deciphera Pharmaceuticals (DCPH), Cassava Sciences (SAVA), Nuvalent (NUVL), Centessa Pharmaceuticals (CNTA), IVERIC bio (ISEE), uniQure (QURE), Zymeworks (ZYME) and Dicerna Pharmaceuticals (DRNA).
View all of BPMUF's competitors.

Basilea Pharmaceutica trades on the OTCMKTS under the ticker symbol "BPMUF."

Shares of BPMUF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BPMUF stock can currently be purchased for approximately $46.00.

Basilea Pharmaceutica has a market capitalization of $494.04 million and generates $136.11 million in revenue each year. The company earns $-15,700,000.00 in net income (profit) each year or ($1.53) on an earnings per share basis.

Basilea Pharmaceutica employs 157 workers across the globe.

The official website for Basilea Pharmaceutica is www.basilea.com.

Basilea Pharmaceutica is headquartered at Grenzacherstrasse 487, Basel V8, 4058.

Basilea Pharmaceutica's mailing address is Grenzacherstrasse 487, Basel V8, 4058. The company can be reached via phone at (161) 606-1111 or via email at [email protected]